PlainRecalls
FDA Drug Critical Class I Terminated

Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.

Reported: June 8, 2022 Initiated: May 11, 2022 #D-0992-2022

Product Description

Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.

Reason for Recall

Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

Details

Units Affected
4224 cartons
Distribution
Distributed Nationwide in the USA
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
Anagrelide Capsules USP, 0.5 mg, 100-count bottles, Rx Only, Manufactured in India For: TEVA PHARMACEUTICALS USA, Inc., North Wales, PA 19454. NDC 0172-5241-60.. Recalled by Teva Pharmaceuticals USA Inc. Units affected: 4224 cartons.
Why was this product recalled?
Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 8, 2022. Severity: Critical. Recall number: D-0992-2022.